for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Deals

Novartis to buy France's CellforCure to boost cell, gene therapy

ZURICH (Reuters) - Novartis NOVN.S is to buy French contract manufacturer CellforCure from biologics company LFB to boost the Swiss drugmaker's capacity to produce cell and gene therapies such as its $475,000 Kymriah cancer treatment.

Novartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure’s facilities to a similar factory in Morris Plains, New Jersey, as well as one under construction in Switzerland. Terms of the cash deal were not given.

Reporting by John Miller; Editing by Kirsten Donovan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up